Synagis (Palivizumab) Biosimilar
RSV Prophylaxis
Early PreclinicalActive
Key Facts
About NeuClone
Australian biosimilar developer using a proprietary CHO platform to bring affordable biologics to market.
View full company profileRSV Prophylaxis
Australian biosimilar developer using a proprietary CHO platform to bring affordable biologics to market.
View full company profile